


M. J. BOND, L. CHU, D. A. NALAWANSHA, K. LI, C. M. CREWS\* (YALE UNIVERSITY, NEW HAVEN, USA)

Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs

ACS Cent. Sci. 2020, 6, 1367–1375, DOI: 10.1021/acscentsci.0c00411.

## A PROTAC for KRAS G12C Degradation



**Significance:** KRAs is one of the most promising cancer drug targets, but targeting it has been a challenge. Crews and co-workers employed covalent KRas G12C inhibitors for the development of PROTACs that allowed for its targeted degradation.

**Comment:** A solvent-exposed site in the clinical drug candidate MRTX849 was identified and used for conjugation to a linker and a VHL ligand to yield the PROTAC LC-2.

**SYNFACTS Contributors:** Dirk Trauner, Johannes Morstein  
Synfacts 2020, 16(11), 1353 Published online: 20.10.2020  
DOI: 10.1055/s-0040-1706368; Reg-No.: T12820SF

© 2020, Thieme. All rights reserved.  
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Category

Chemistry in  
Medicine and  
Biology

Key words

KRAS  
targeted  
degradation  
cancer  
drug development

Synfact  
of the  
Month

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.